Boston Scientific Corporation (BSX)

Check out top investors' recommendation for BSX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. The company offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products, such as balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty; intraluminal ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides cardiac rhythm management devices consisting of implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; and implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker systems to treat heart failure. In addition, the company offers endoscopy products, such as devices to treat diseases of the digestive and pulmonary systems; and peripheral interventions to diagnose and treat peripheral vascular disease. Further, it provides stone management products comprising ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons, and catheters to treat urinary stone disease and benign prostatic hyperplasia; and mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices for women's health. Additionally, it provides neuromodulation products used for the management of chronic pain; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart, such as radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. The company was founded in 1979 and is headquartered in Natick, Massachusetts.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Bruce Nudell Credit Suisse Buy   Aug 15, '18     40.00  Aug 15, '19  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Aug 08, '18     40.00  Aug 08, '19  N/A 
Jason Mills Canaccord Genuity Buy   Aug 08, '18     39.00  Aug 08, '19  N/A 
Michael Matson Mizuho Securities USA Buy   Aug 08, '18     39.00  Aug 08, '19  N/A 
Amit Hazan Suntrust Robinson Humphrey Buy   Jun 22, '18     37.00  Jun 22, '19  N/A 
Chris Cooley Stephens Inc. Buy   Jun 12, '18     34.00  Jun 12, '19  N/A 
Bob Hopkins BofA Merrill Lynch Buy   Apr 05, '18     34.00  Apr 05, '19  N/A 
Jason Mills Canaccord Genuity Buy   Mar 22, '18     35.00  Mar 22, '19  N/A 
Michael Matson Mizuho Securities USA Buy   Mar 21, '18     35.00  Mar 21, '19  N/A 
David Lewis Morgan Stanley Buy   Mar 19, '18     33.00  Mar 19, '19  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Feb 23, '18     31.00  Feb 23, '19  N/A 
Rick Wise Stifel Nicolaus & Company, Inc. Buy   Feb 01, '18     31.00  Feb 01, '19  N/A 
Glenn Novarro RBC Capital Markets Buy   Feb 01, '18     32.00  Feb 01, '19  N/A 
Jason Mills Canaccord Genuity Buy   Jan 17, '18     35.00  Jan 17, '19  N/A 
Michael Matson Mizuho Securities USA Buy   Jan 16, '18     32.00  Jan 16, '19  N/A 
Danielle Antalffy Leerink Swann Llc Buy   Jan 09, '18       Jan 09, '19  N/A 
Matthew Taylor National Bank Financial Buy   Jan 09, '18     32.00  Jan 09, '19  N/A 
Sean Lavin Lazard Capital Markets Buy   Jan 09, '18     31.00  Jan 09, '19  N/A 
Michael Matson Mizuho Securities USA Buy   Dec 08, '17     32.00  Dec 08, '18  N/A 
Bruce Nudell Credit Suisse Buy   Dec 01, '17     33.00  Dec 01, '18  N/A 
< previous12345